Abbott Laboratories (ABT)vsBoston Scientific Corp (BSX)
ABT
Abbott Laboratories
$86.30
-1.00%
HEALTHCARE · Cap: $155.82B
BSX
Boston Scientific Corp
$56.00
+0.04%
HEALTHCARE · Cap: $83.97B
Smart Verdict
WallStSmart Research — data-driven comparison
Abbott Laboratories generates 119% more annual revenue ($45.13B vs $20.61B). BSX leads profitability with a 17.3% profit margin vs 13.9%. BSX appears more attractively valued with a PEG of 0.68. BSX earns a higher WallStSmart Score of 71/100 (B).
ABT
Buy56
out of 100
Grade: C
BSX
Strong Buy71
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+0.4%
Fair Value
$87.53
Current Price
$86.30
$1.23 discount
Margin of Safety
-21.3%
Fair Value
$46.16
Current Price
$56.00
$9.84 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Strong operational efficiency at 20.6%
Generating 1.0B in free cash flow
Areas to Watch
Moderate valuation
Weak financial health signals
Earnings declined 19.7%
No major concerns identified
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap, Price/Book. PEG of 1.33 suggests the stock is reasonably priced for its growth.
Bull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bear Case : ABT
The primary concerns for ABT are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : BSX
No major red flags identified for BSX, but monitor valuation.
Key Dynamics to Monitor
ABT profiles as a value stock while BSX is a mature play — different risk/reward profiles.
BSX carries more volatility with a beta of 0.78 — expect wider price swings.
BSX is growing revenue faster at 11.6% — sustainability is the question.
BSX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
BSX scores higher overall (71/100 vs 56/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?